tumour infiltrating lymphocytes

Cell therapyexperimental

Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis. — Wikipedia

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • tumor infiltrating lymphocyte
  • tumor infiltrating lymphocytes
  • tumor-infiltrating lymphocytes
  • tumour infiltrating lymphocytes

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06630611Phase 2Dec 31, 2024Banc de Sang i Teixits, Universidad Autonoma de Barcelona
NCT06626256Phase 1Dec 30, 2024City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06375187Phase 1May 29, 2024Government of China
NCT06047977Phase 1Feb 1, 2024Cannonball Kids' Cancer Foundation, Johns Hopkins University, Swim Across America, University of South Florida
NCT06107894Phase 1Jan 31, 2024Neogen, University of Ulsan
NCT05649618Early Phase 1 (Phase 1)Dec 5, 2022Fujian Medical University
NCT05087745Early Phase 1 (Phase 1)Dec 10, 2021Shanghai Gencells Therapeutics Co., Ltd., Zhejiang University
NCT03526185Early Phase 1 (Phase 1)Feb 6, 2018Yale University
NCT03166397Phase 2Jun 1, 2017Tel Aviv University
NCT03158935Phase 1Jun 1, 2017Merck, University of Toronto
NCT02926053Phase 1Dec 1, 2016University of Copenhagen
NCT02652455Early Phase 1 (Phase 1)Mar 2, 2016Bristol-Myers Squibb, Iovance, Prometheus Inc., University of South Florida
NCT02500576Phase 2Aug 7, 2015Merck, Prometheus Inc., University of Texas at Houston
NCT02482090Phase 1Jul 1, 2015University of Copenhagen
NCT02421640Phase 2Mar 1, 2015Sun Yat-Sen University
NCT01883297Phase 1Jan 1, 2015University of Toronto
NCT02379195Phase 1/Phase 2 (Phase 2)Nov 1, 2014University of Copenhagen
NCT02354690Phase 1/Phase 2 (Phase 2)Nov 1, 2014University of Copenhagen
NCT01995344Phase 2Oct 1, 2013National Institute for Health Research, United Kingdom, The Christie NHS Foundation Trust, University of Manchester
NCT01807182Phase 2Jul 26, 2013National Cancer Institute (NCI), University of Washington
Showing 20 of 46 trials
Page 1 / 3

Organizations

Research & Development (39)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government18721994
National Institutes of Health (NIH)Government7422003
University of South FloridaAcademic/Hospital5532009
University of CopenhagenAcademic/Hospital4422014
University of WashingtonAcademic/Hospital3321995
Bristol-Myers SquibbFor profit2022012
IovanceFor profit2022012
Johns Hopkins UniversityAcademic/Hospital2222007
MerckFor profit2022015
Prometheus Inc.For profit2022015
Sun Yat-Sen UniversityAcademic/Hospital2222011
University of TorontoAcademic/Hospital2212015
Banc de Sang i TeixitsAcademic/Hospital1012024
Cancer Biotherapy Research GroupAcademic/Hospital1011996
Cannonball Kids' Cancer FoundationAcademic/Hospital1012024
City of Hope National Medical CenterAcademic/Hospital1112024
Fujian Medical UniversityAcademic/Hospital1112022
Government of ChinaGovernment1112024
Hebrew UniversityAcademic/Hospital1112008
Hoag Memorial Hospital PresbyterianAcademic/Hospital1111996
39 organizations
Page 1 / 2